ALLO Stock Analysis: Buy, Sell, or Hold?
ALLO - Allogene Therapeutics, Inc. Common Stock
$2.14
-0.19 (-8.15%)
▼
5d:
-5.73%
30d:
-1.38%
90d:
+32.1%
HOLD
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Smart Money Accumulation
ALLO is down 5.7% this week, but smart money is accumulating calls. Top strike: $2.5 2026-06-18 with 1,118 OI. Call ratio: 100% View Scanner →
Strength: 7.9/10
Get Alerted When ALLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ALLO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ALLO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ALLO is currently trading at $2.14, which is considered oversold relative to its 30-day fair value range of $2.14 to $2.60.
Technical Outlook: Technically, ALLO is in a strong uptrend. The price is currently testing key support at $2.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.65 (+304.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALLO is in a strong uptrend. The price is currently testing key support at $2.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.65 (+304.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.14 -
$2.60
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.2%)
- BULLISH: Trading 304.4% below Wall St target ($8.65)
- CAUTION: Recommendation downgraded due to -5.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.14 -
$2.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.08
Resistance Level
$2.39
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.07
Wall Street Target
$8.65
(+304.4%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: May 14, 2026 8:16 PM ET
Data refreshes hourly during market hours. Next update: 9:16 PM
Data refreshes hourly during market hours. Next update: 9:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Annie Yoshiyama
SELL
9586 shares
2026-04-21
Benjamin Machinas Beneski
SELL
2867 shares
2026-03-31
Benjamin Machinas Beneski
SELL
4835 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 58 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 59 HOLD |
